Crossmark

Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system

Crossref DOI link: https://doi.org/10.1186/s12879-023-08103-4

Published Online: 2023-03-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Enayatrad, Mostafa

Mahdavi, Sepideh

Aliyari, Roqayeh

Sahab-Negah, Sajad

Nili, Sairan

Fereidouni, Mohammad

Mangolian Shahrbabaki, Parvin

Ansari-Moghaddam, Alireza

Heidarzadeh, Abtin

Shahraki-Sanavi, Fariba

Fateh, Mansooreh

Khajeha, Hamidreza

Emamian, Zahra

Behmanesh, Elahe

Sheibani, Hossein

Abbaszadeh, Maryam

Jafari, Reza

Valikhani, Maryam

Binesh, Ehsan

Vahedi, Hamid

Chaman, Reza

Sharifi, Hamid

Emamian, Mohammad Hassan http://orcid.org/0000-0002-1994-1105
Funding

Funding for this research was provided by:

Shahroud University of Medical Sciences (99135)

Vice-chancellery for research and technology at Iranian Ministry of Health and Medical Education (2302)

World Health Organization (2021/1169483-0, 2022/1217943-1)
License Information

Text and Data Mining valid from 2023-03-10

Version of Record valid from 2023-03-10
More Information

Article History

Received: 25 August 2022

Accepted: 19 February 2023

First Online: 10 March 2023

Declarations

:

: This study was approved by the ethics committee of Shahroud University of Medical Sciences, Shahroud, Iran with the reference number of IR.SHMU.REC.1400.012. Participation in this study was entirely voluntary, and after explaining the study objectives and methods, a written consent form was obtained from all participants.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below